Other reported combination immunotherapy studies are encouraging and really open new avenues for HCC treatment [128–130], however, additional strategies are needed to uncover more sensitive predictive biomarkers besides PD-1/PD-L1 axis, optimize treatment selection, and improve HCC patients immune response. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.